RVNC: Revance Therapeutics Inc Company Profile & Statistics

About

Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS? peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform.

Info & Links

CEO

Mark J. Foley

Headquarters

1222 DEMONBREUN STREET, SUITE 2000
NASHVILLE, TN 37203, UNITED STATES

Auditor

PricewaterhouseCoopers LLP

Share holders

155

Employees

597

Revance Therapeutics Inc Statistics

Valuation Measures

Market Capitalization²

322.04M

Enterprise Value

705.02M

Enterprise Value/EBITDA(ttm)

-2.47

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

1.30

Price to Book(mrq)

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

70.11%

Operating Margin(ttm)

-73.20%

Profit Margin(ttm)

-73.29%

Return on Equity(ttm)

Return on Invested Capital(ttm)

-107.42%

Return on Assets(ttm)

-37.22%

Income Statement

Revenue(ttm)

256.94M

Revenue Per Share(ttm)

2.45

Gross Profit(ttm)

179.32M

EBITDA(ttm)³

-285.71M

Net Income Available to Common(ttm)

-184.44M

Diluted EPS(ttm)

-1.93

Share Statistics

Beta (5Y Monthly)

0.81

52-Week Change

-58.68%

S&P 500 52-Week Change

24.87%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

104.90M

Dividend Yield

0.00%

Float⁴

99.07M

% Held by Insiders

5.10%

% Held by Institutions

97.70%

Balance Sheet

Total Cash(mrq)

184.54M

Total Cash Per Share(mrq)

1.76

Total Debt(mrq)

442.03M

Total Debt/Equity(mrq)

-271.14%

Current Ratio(mrq)

4.12%

Quick Ratio(mrq)

3.05%

Book Value Per Share(mrq)

-1.55

Cash Flow

Operating Cash Flow Per Share(ytd)

-1.42

Free Cash Flow(ytd)

-150.40M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

RVNC

Revance Therapeutics Inc

Revance Therapeutics Inc Profile